Cardiology Research

“A Phase 2B Randomized Double-Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of JVS-100 Administered by Direct Intramuscular Injection as Adjunct to Revascularization of Infrapopliteal Lesions in Subjects with Advanced Peripheral Artery Disease (PAD) and Tissue Loss (Ulceration and/or Gangrene)” (Juventa Therapeutics, Inc. JTCS-007) (Protocol #16-05-H-01)

If you are suffering from pain or cramps in your legs, you may have peripheral artery disease. Peripheral artery disease (PAD) is caused by plaque buildup in the arteries of your legs. Patients with PAD often develop large, non-healing foot wounds.

We are conducting a clinical trial in patients with PAD and non-healing foot wounds. We are studying an injectable medication to see if it can increase the healing of foot wounds in patients after endovascular or surgical opening of the arteries of the legs.

If you are scheduled for an endovascular or surgical procedure for PAD and you have a non-healing foot wound, please contact our research team at 305-674-2121 ext 56022 or 305-674-2121 ext 59118.


“OPUS Registry (Opsumit Users Registry)” (Protocol #15-21-H-04)

We are currently recruiting patients being treated with Opsumit® (macitentan) for Pulmonary Arterial Hypertension (“PAH”) or another disease.  You may be a candidate for the trial if you:

  • Are receiving treatment with Opsumit® (macitentan) for Pulmonary Arterial Hypertension (“PAH”) or another disease;
  • Are 18 years of age or older;

For more information, please contact (305) 674-2162.


Effect of “Vaping” Electronic Cigarettes on Endothelial Function in Healthy Adults (Protocol #14-18-H-03)

We are currently recruiting healthy men and women to assess their endothelial function (the function of the vessels) after smoking electronic cigarettes. You may be a candidate for the trial if you…

  • Are 18 year of age of older.
  • Have NOT used tobacco or any of the nicotine containing products such as gum, patches, lozenges, inhalers, sprays, etc. (i.e. Nicoderm, Nicorette, etc) in the past 6 months.
  • Have NO intolerance or hypersensitivity to nicotine.
  • Have NO History of coronary disease or peripheral artery disease.
  • Are not participating in any other research studies.
  • Meet other qualifications.

If you qualify to take part in this study, there will not be any additional cost to you.

Please call 305-674-2162 to learn if you might be eligible to take part in this study. Fax communications can be sent to 305-674-2169.


Urine Metals and Endothelial Function after a Single TACT Infusion in TACT-eligible Patients TACT-EndoMetal (Protocol # 14-35-H-07)

The Cardiology Department is recruiting patients for a research study to measure the levels of toxic metals in urine before and after the administration of a chelating solution.

If you qualify to take part in this study, there will be no additional cost to you.

Please call 305-674-2162 to learn if you might be eligible to take part in this study.


Pilot Trial of Limb Preservation Using Chelation Therapy in Diabetic Patients with Critical Limb Ischemia (Protocol # 14-36-H-07)

The Cardiology Department is recruiting patients with diabetes and severe peripheral artery disease for a research study to determine if chelation therapy will improve outcomes and delay or reduce amputations.

If you qualify to take part in this study, there will be no additional cost to you.

Please call 305-674-2162 to learn if you might be eligible to take part in this study.


Clinical Outcomes Assessment of the MitraClip Percutaneous Therapy for High Surgical Risk Patients (The COAPT Trial) (Protocol # 12-63-H-11)

The Cardiology Department is recruiting patients diagnosed with functional mitral regurgitation (FMR).  You might be a candidate for the study if you:

  • Have moderate-to-severe or severe functional mitral regurgitation and you have been determined to be too high risk for mitral valve surgery;
  • Are 18 years of age or older

If you qualify to take part in this study, there will not be any additional cost to you.  Please call 305-674-2162 to learn if you might be eligible to take part in this study.


“A Randomized, Double-Blind, Placebo-Controlled, Event-Driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-Myocardial Infarction Patients with Elevated hsCRP” (Protocol #11-11-H-04)

We are currently recruiting patients who have suffered a heart attack to take part in a research study. You may be a candidate if you:

  • Have a history of Myocardial Infarction more than 30 days ago
  • Are older than 18 years of age
  • Other requirements apply

If you qualify to take part in this study, there will not be a compensation for your participation. If you are interested in taking part in this study, call 305-674-2162 or send a fax to 305-674-2169.